John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
Global
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
2
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
4
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC
5